Straits Times Index
3,426.47 -3.98 (-0.12%) Nikkei
37,667.41 -202.10 (-0.53%) Hang Seng
17,021.31 +16.34 (+0.10%) FTSE 100
8,285.71 +99.36 (+1.21%) Bitcoin USD
69,342.35 +1,612.77 (+2.38%) CMC Crypto 200
1,400.57 +69.97 (+5.26%)
Intellia Therapeutics, Inc. (NTLA)
After hours:
| Previous close | 26.42 |
| Open | 26.84 |
| Bid | 26.43 x 200 |
| Ask | 26.53 x 900 |
| Day's range | 26.27 - 27.42 |
| 52-week range | 19.37 - 43.06 |
| Volume | |
| Avg. volume | 1,691,732 |
| Market cap | 2.557B |
| Beta (5Y monthly) | 1.81 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.37 |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 69.61 |
ZacksIntellia (NTLA) to Report Q2 Earnings: What's in the Cards?
On Intellia's (NTLA) second-quarter 2024 earnings call, investors' focus is likely to be on the progress of its pipeline of genome-editing candidates.
GlobeNewswireIntellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that it awarded inducement grants on July 22, 2024 to its Executive Vice President and Chief Financial Officer, Edward Dulac, under Intellia’s 2024 Inducement Plan as a material inducement to employment. The inducement grants consisted of non-qualified stock options to purchase
Simply Wall St.We're Keeping An Eye On Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
